

Serial No. 10/042,818

Supplemental Amendment to Amendment of 10/14/03

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A topical composition ~~[[comprising]]~~ consisting essentially of, on a weight basis:

0.1-18% of L arginine;

1-15% of lidocaine; and

a pharmaceutically acceptable carrier which includes liposomes disposed in a continuous phase; wherein said lidocaine is disposed within said liposomes, and said L arginine is in said continuous phase.

2. (Cancelled)

2 3. (Original) The composition of claim 1, wherein said lidocaine is present in a weight amount of 1-10%.

3 4. (Original) The composition of claim 1, wherein said lidocaine is present in a weight amount of 5%.

4 5. (Original) The composition of claim 1, wherein said L arginine comprises 0.1-3 weight percent of said composition.

5 6. (Original) The composition of claim 1, wherein said L arginine comprises, on a weight basis, 1% of said composition.

Serial No. 10/042,818

Supplemental Amendment to Amendment of 10/14/03

647-6000 (248) 647-6000
18009-5394
280 N. OLD WOODWARD AVENUE, STE. 400, BIRMINGHAM, MICHIGAN 48009-5394
ANDERSON & CITKOWSKI, P.C.
GIFFORD, KRASS, GROH, SPRINKLE

6 7. (Original) The composition of claim 1, wherein said L arginine is present as a salt.

8. (Cancelled)

9. (Cancelled)

10 10. (Currently Amended) The composition of claim ⁷[[9]] 27, wherein said topical corticosteroid is hydrocortisone or a derivative thereof.

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Cancelled)

16. (Cancelled)

Serial No. 10/042,818

Supplemental Amendment to Amendment of 10/14/03

17. (Cancelled)

18. (Cancelled)

11 19. (Currently Amended) A method for treating an anorectal disorder in a patient, said method comprising applying to the affected area of said patient a composition ~~comprising~~ consisting essentially of L arginine, a local anesthetic and a pharmaceutically acceptable carrier comprising liposomes disposed in a continuous phase;

wherein, said local anesthetic is disposed within said liposomes, and said L arginine is in said continuous phase.

12 20. (Original) The method of claim 19, wherein said local anesthetic comprises lidocaine.

21. (Cancelled)

13 22. (Original) The method of claim 19, wherein said L arginine comprises, on a weight basis, 0.1-5% of said composition.

23. (Cancelled)

24. (Cancelled)

Serial No. 10/042,818

Supplemental Amendment to Amendment of 10/14/03

25. (Cancelled)

26. (Cancelled)

7 27. (New) A topical composition consisting essentially of, on a weight basis:

0.1 - 18% of L arginine;

1 - 15% of lidocaine;

a topical corticosteroid; and

a pharmaceutically acceptable carrier which includes liposomes disposed in a continuous phase; and

wherein said lidocaine is disposed within said liposomes, and said L arginine is in said continuous phase.

8 28. (New) A topical composition consisting essentially of, on a weight basis:

0.1 - 18% of L arginine;

1 - 15% of lidocaine; and

a material selected from the group consisting of: diltiazem, indomethacin, piroxicam, naproxen, ibuprofen, sildenafil, allantoin, phenylephrine, combinations of the foregoing, and salts of the foregoing.

Serial No. 10/042,818

Supplemental Amendment to Amendment of 10/14/03

9 29. (New) A method for treating anorectal disorder in a patient, said method comprising applying to the affected area of said patient a composition consisting essentially of:

L arginine;

a local anesthetic;

a material selected from the group consisting of: diltiazem, indomethacin, piroxicam, naproxen, ibuprofen, sildenafil, allantoin, phenylephrine, a topical corticosteroid, combinations of the foregoing, and salts of the foregoing;

a pharmaceutically acceptable carrier comprising liposomes disposed in a continuous phase;

and

wherein, said local anesthetic is disposed within said liposomes, and said L arginine is in said continuous phase.